Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stok Raporu

Piyasa değeri: US$90.8b

Regeneron Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 36.83 years. total yearly compensation is $8.18M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 2.22% of the company’s shares, worth $2.01B. The average tenure of the management team and the board of directors is 7.2 years and 17.9 years respectively.

Anahtar bilgiler

Leonard Schleifer

İcra Kurulu Başkanı

US$8.2m

Toplam tazminat

CEO maaş yüzdesi22.9%
CEO görev süresi36.8yrs
CEO sahipliği2.2%
Yönetim ortalama görev süresi7.2yrs
Yönetim Kurulu ortalama görev süresi17.9yrs

Son yönetim güncellemeleri

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Recent updates

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

CEO Tazminat Analizi

Leonard Schleifer'un ücretlendirmesi Regeneron Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

US$5b

Jun 30 2024n/an/a

US$4b

Mar 31 2024n/an/a

US$4b

Dec 31 2023US$8mUS$2m

US$4b

Sep 30 2023n/an/a

US$4b

Jun 30 2023n/an/a

US$4b

Mar 31 2023n/an/a

US$4b

Dec 31 2022US$7mUS$2m

US$4b

Sep 30 2022n/an/a

US$5b

Jun 30 2022n/an/a

US$6b

Mar 31 2022n/an/a

US$8b

Dec 31 2021US$6mUS$2m

US$8b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$6b

Mar 31 2021n/an/a

US$4b

Dec 31 2020US$135mUS$1m

US$4b

Sep 30 2020n/an/a

US$3b

Jun 30 2020n/an/a

US$3b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$21mUS$1m

US$2b

Sep 30 2019n/an/a

US$2b

Jun 30 2019n/an/a

US$2b

Mar 31 2019n/an/a

US$2b

Dec 31 2018US$27mUS$1m

US$2b

Sep 30 2018n/an/a

US$2b

Jun 30 2018n/an/a

US$2b

Mar 31 2018n/an/a

US$1b

Dec 31 2017US$27mUS$1m

US$1b

Tazminat ve Piyasa: Leonard's total compensation ($USD8.18M) is below average for companies of similar size in the US market ($USD12.87M).

Tazminat ve Kazançlar: Leonard's compensation has been consistent with company performance over the past year.


CEO

Leonard Schleifer (71 yo)

36.8yrs

Görev süresi

US$8,184,338

Tazminat

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Leonard Schleifer
Co-Founder36.8yrsUS$8.18m2.22%
$ 2.0b
George Yancopoulos
Co-Founder23.8yrsUS$7.76m1.07%
$ 970.1m
Andrew Murphy
Executive Vice President of Research5.8yrsUS$8.43m0.049%
$ 44.3m
Daniel Van Plew
Executive VP and GM of Industrial Operations & Product Supply16.6yrsUS$8.76m0.031%
$ 28.5m
Christopher Fenimore
Senior VP of Finance & CFOless than a yearVeri yok0.017%
$ 15.8m
Patrice Gilooly
Senior Vice President of Quality Assurance & Operations4.8yrsVeri yokVeri yok
Bob McCowan
Senior VP of IT & Chief Information Officer3.8yrsVeri yokVeri yok
Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysisno dataVeri yokVeri yok
Joseph LaRosa
Executive VP13.2yrsUS$7.13m0.035%
$ 32.2m
Melissa Lozner
Senior VP & Chief Compliance Officer1.8yrsVeri yokVeri yok
Christina Chan
Senior Vice President of Corporate Affairsno dataVeri yokVeri yok
Sally Paull
Executive Vice President of Human Resources8.6yrsVeri yokVeri yok

7.2yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim: REGN's management team is seasoned and experienced (7.2 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Leonard Schleifer
Co-Founder36.8yrsUS$8.18m2.22%
$ 2.0b
George Yancopoulos
Co-Founder23.8yrsUS$7.76m1.07%
$ 970.1m
Christine Poon
Lead Independent Director14yrsUS$748.01k0.00073%
$ 662.6k
Arthur Ryan
Independent Director21.8yrsUS$724.99k0.016%
$ 14.8m
Michael Brown
Independent Director33.4yrsUS$728.99k0.012%
$ 10.5m
Joseph Goldstein
Independent Director33.4yrsUS$709.99k0.0046%
$ 4.2m
George Sing
Independent Director36.8yrsUS$724.99k0.026%
$ 23.9m
N. Coles
Independent Director7.8yrsUS$704.99k0.000010%
$ 9.1k
Craig Thompson
Independent Director2.1yrsUS$247.79k0%
$ 0
Huda Zoghbi
Independent Director8.2yrsUS$714.99k0%
$ 0
Bonnie Bassler
Independent Director8.2yrsUS$709.99k0.0013%
$ 1.2m
Kathryn Guarini
Independent Director1.2yrsUS$1.03m0%
$ 0

17.9yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: REGN's board of directors are seasoned and experienced ( 17.9 years average tenure).